Long Of The Year: CELGENE

It is a bit early but I figured I better get it out there before it skyrockets. I searched over many stocks that I thought had huge potential and Celgene (CELG) was the winner. Other finalist are Intuitive Surgical (ISRG), Kohls (KSS), Amylin (AMLN), and Apple (AAPL). I really like all the other stocks but Celgene is heads and shoulders above them for one reason. Growth. All it needed to move above all other stocks was approval for its drug Revlimid. If want more on the approval here is the full story The reason it is such a growth story is this drug has the potential to be a multi-billion dollar drug. It will cost the average patient $54,000 a year to use it and there are presently 10,000-20,000 patients. This also will be prescribed “off-label” to Multiple Myeloma or MM which has thousands more patients. The pipeline is as deep as any biotech in the industry and if stem cells ever do get to the point they provide revenue, Celgene has a one of the top stem cell units. Management is another important part of a good company. Although the CEO is stepping down, Sol Barer the present COO, has been with Celgene since 1986 and should have no problem stepping into Jackson’s shoes. Presently analyst have sales of 2008 at $700-800 millions dollars and that is way, way off. The thought it would cost $30,000 per patient and we know that is way off. The analyst in general have had a tough time with this one and have missed this stock for the last ten years. It was up 113% and growing this year and in May of 1990 could have been had for a split adjusted 90 cents. Now I know there have been some people that have had the stock all along but one person has been all over this stock on a daily basis and that is Rob_Cos of the Yahoo Message Board. He can answer any question you have about Celgene and is the biggest long I’ve ever me. He will be proven correct again this year with the recent approval. If there is one stock to go HUGE on this year. Celgene is the stock.

 

 

 

 

Comments